ARDX ARDELYX, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1437402 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.6%
TTM net income YoY1.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—
Margins
Gross margin94.5%
Operating margin-7.7%
Net margin-11.8%
FCF margin-3.4%
EBITDA margin-7.1%
Returns
ROE-34.9%
ROA-10.3%
ROIC (approx.)-8.3%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets72.1%
Debt / equity1.54x
Current ratio3.45x
Interest coverage-1.63x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $407.32M | $333.62M | $124.46M | $52.16M | $10.10M |
| Cost of revenue | $39.54M | $50.56M | $17.80M | $4.12M | $1.00M |
| Gross profit | $367.78M | $283.06M | $106.66M | $48.04M | $9.10M |
| R&D expense | $71.53M | $52.32M | $35.54M | $35.20M | $91.14M |
| SG&A expense | $337.23M | $258.69M | $134.40M | $76.60M | $72.30M |
| Operating income | -$40.98M | -$27.95M | -$63.28M | -$63.76M | -$154.35M |
| Interest expense | $20.10M | $13.01M | $4.95M | $3.40M | $4.50M |
| Pretax income | -$60.63M | -$38.87M | -$65.52M | -$67.20M | -$158.16M |
| Income tax | $969,000 | $266,000 | $547,000 | $8,000 | $4,000 |
| Net income | -$61.60M | -$39.14M | -$66.07M | -$67.21M | -$158.16M |
| EBITDA | -$37.92M | -$25.89M | -$61.98M | -$62.62M | -$151.54M |
| EPS (basic) | -0.26 | -0.17 | -0.30 | -0.42 | -1.52 |
| EPS (diluted) | -0.26 | -0.17 | -0.30 | -0.42 | -1.52 |
| Weighted avg. shares (diluted) | 241.03M | 235.23M | 219.33M | 158.69M | 104.21M |
| Balance sheet | |||||
| Cash & equivalents | $68.00M | $64.93M | $21.47M | $96.14M | $72.43M |
| Short-term investments | $196.69M | $185.17M | $162.83M | $27.77M | $44.26M |
| Receivables | $71.85M | $57.70M | $22.03M | $7.73M | $502,000 |
| Inventory | $123.11M | $91.18M | $49.49M | $28.35M | $0 |
| Current assets | $382.32M | $356.45M | $246.11M | $153.60M | $133.65M |
| PP&E, net | $2.18M | $1.50M | $1.01M | $1.22M | $2.36M |
| Total assets | $501.60M | $435.75M | $297.58M | $190.07M | $149.91M |
| Current liabilities | $88.61M | $77.83M | $50.39M | $65.60M | $52.82M |
| Short-term debt | — | — | — | — | $32.26M |
| Long-term debt | $202.83M | $150.85M | $49.82M | $26.71M | $32.26M |
| Total debt | $202.83M | $150.85M | $49.82M | $26.71M | $64.53M |
| Total liabilities | $334.65M | $262.46M | $130.76M | $91.74M | $67.30M |
| Shareholders' equity | $166.95M | $173.29M | $166.82M | $98.33M | $82.62M |
| Net debt | $134.84M | $85.92M | $28.35M | -$69.43M | -$7.90M |
| Shares outstanding | 244.35M | 238.02M | 232.45M | 198.58M | 130.18M |
| Cash flow statement | |||||
| Operating cash flow | -$42.48M | -$44.81M | -$89.72M | -$70.04M | -$152.55M |
| Capital expenditure | $1.49M | $1.01M | $344,000 | $55,000 | $1.87M |
| Free cash flow | -$43.98M | -$45.82M | -$90.06M | -$70.10M | -$154.42M |
| Investing cash flow | -$8.96M | -$18.32M | -$131.25M | $18.41M | $50.95M |
| Financing cash flow | $54.51M | $106.59M | $146.29M | $75.34M | $83.00M |
| Depreciation & amortization | $3.06M | $2.06M | $1.29M | $1.14M | $2.81M |
| Stock-based compensation | $48.96M | $37.38M | $13.53M | $10.75M | $12.04M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.